⌕
Allogene Therapeutics · ALLO · Nasdaq
Tenet 65 · Solid
Compare
$0.70−6.48%At closeTenet 65 · Solid
$0.70−0.05 (−6.48%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

Allogene Therapeutics (ALLO) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ALLO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 16, 2026 · 09:52 ET
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript

Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript…

ALLO −6.5% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 13:41 ET
Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript

Allogene Therapeutics, Inc. ( ALLO ) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases November 9, 2026 9:00 AM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affai…

ALLO −6.5% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

ALLO −6.5% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 13:54 ET
Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call Transcript

Allogene Therapeutics, Inc. ( ALLO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President…

ALLO −6.5% todayRead at source ↗
● MarketBeatNov 5, 2026 · 19:15 ET
Allogene Therapeutics Q3 Earnings Call Highlights

Allogene Therapeutics NASDAQ: ALLO expects to complete enrollment in its ALPHA3 lymphoma trial by the end of 2027, as increased screening and activity in Asia-Pacific help support recruitment, executives said on the comp…

ALLO −6.5% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

ALLO −6.5% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

ALLO −6.5% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

ALLO −6.5% todayRead at source ↗
● GlobeNewsWireOct 26, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

ALLO −6.5% todayRead at source ↗
● Defense WorldSep 28, 2026 · 03:23 ET
3,187,320 Shares of Allogene Therapeutics, Inc. $ALLO Acquired by Bank of America Corp DE

Bank of America Corp DE bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission.…

ALLO −6.5% todayRead at source ↗
● Zacks Investment ResearchSep 11, 2026 · 12:31 ET
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?…

ALLO −6.5% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 12:17 ET
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

ALLO −6.5% todayRead at source ↗
● Defense WorldSep 7, 2026 · 04:20 ET
Frazier Life Sciences Management L.P. Acquires 18,650,000 Shares of Allogene Therapeutics, Inc. $ALLO

Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 491.2% during a recent quarter, according to its most recent disclosure with the Securities and Exchange …

ALLO −6.5% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for c…

ALLO −6.5% todayRead at source ↗
● Defense WorldSep 2, 2026 · 03:52 ET
Deutsche Bank AG Purchases Shares of 281,949 Allogene Therapeutics, Inc. $ALLO

Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in a recent quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 281,9…

ALLO −6.5% todayRead at source ↗
● Defense WorldSep 1, 2026 · 03:58 ET
Connor Clark & Lunn Investment Management Ltd. Invests $671,000 in Allogene Therapeutics, Inc. $ALLO

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) during a recent quarter, according to the company in its most recent filing with the Secur…

ALLO −6.5% todayRead at source ↗
● GlobeNewsWireAug 31, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Allogene Therapeutics Announces Participation in September Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

ALLO −6.5% todayRead at source ↗
● Seeking AlphaAug 28, 2026 · 18:21 ET
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?

Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations su…

ALLO −6.5% todayRead at source ↗
● Defense WorldAug 28, 2026 · 03:59 ET
Allogene Therapeutics, Inc. $ALLO Shares Acquired by Bank of America Corp DE

Bank of America Corp DE lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 111.9% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchan…

ALLO −6.5% todayRead at source ↗
NVDA16−2.9%
ANT13
MSFT5+0.4%
P4−1.0%

Article counts from the last market-wide feed page, across every symbol we track and not just ALLO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.